{"id":48835,"date":"2026-10-29T16:24:18","date_gmt":"2026-10-29T15:24:18","guid":{"rendered":"https:\/\/www.satt.fr\/?p=48835"},"modified":"2026-10-29T17:40:04","modified_gmt":"2026-10-29T16:40:04","slug":"nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus","status":"publish","type":"post","link":"https:\/\/www.satt.fr\/en\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\/","title":{"rendered":"Nouvelle avanc\u00e9e pour la startup AdipoPharma, propuls\u00e9e par Conectus"},"content":{"rendered":"<p><span style=\"color: #c90f4c;\"><strong>AdipoPharma, cr\u00e9\u00e9e en 2017, poursuit un d\u00e9veloppement prometteur. Sa mol\u00e9cule PATAS entre en phase d\u2019\u00e9tude clinique 1b chez des patients atteints de diab\u00e8te de type 2. Une avanc\u00e9e majeure pour cette biotech strasbourgeoise, qui illustre concr\u00e8tement l&#8217;apport du transfert de technologie port\u00e9 par Conectus : transformer des d\u00e9couvertes scientifiques en innovations-sant\u00e9 au b\u00e9n\u00e9fice de toute la soci\u00e9t\u00e9.<\/p>\n<p><\/strong><\/span><\/p>\n<p>Une nouvelle \u00e9tape vient d\u2019\u00eatre franchie par AdipoPharma. PATAS, sa prometteuse mol\u00e9cule pour traiter le diab\u00e8te de type 2, entre en phase d\u2019\u00e9tude clinique 1b, avec un d\u00e9ploiement pr\u00e9vu aupr\u00e8s de patients atteints de diab\u00e8te de type 2.<\/p>\n<p><span style=\"font-size: 14pt; color: #c90f4c;\"><strong>De la recherche au patient : une avanc\u00e9e d\u00e9cisive<\/strong><\/span><\/p>\n<p>L\u2019ambition de cette innovation est de proposer une nouvelle approche th\u00e9rapeutique en ciblant directement la r\u00e9sistance \u00e0 l\u2019insuline, m\u00e9canisme central de cette maladie m\u00e9tabolique. L\u00e0 o\u00f9 les traitements existants agissent notamment sur la r\u00e9gulation de la glyc\u00e9mie et les cons\u00e9quences de la maladie, PATAS vise \u00e0 intervenir sur l\u2019un de ses m\u00e9canismes biologiques sous-jacents. Cette nouvelle \u00e9tape clinique prolonge des r\u00e9sultats pr\u00e9cliniques et clinique phase 1a prometteurs.<\/p>\n<p><span style=\"color: #c90f4c;\"><strong>Conectus, partenaire de la 1\u00e8re heure<br \/><\/strong><\/span><br \/>Derri\u00e8re cette trajectoire, des travaux men\u00e9s \u00e0 l&#8217;origine par le <strong>Laboratoire de G\u00e9n\u00e9tique M\u00e9dicale (Inserm \/ Universit\u00e9 de Strasbourg)<\/strong>, autour des m\u00e9canismes de la r\u00e9sistance \u00e0 l\u2019insuline. Coordonn\u00e9e par <strong><a href=\"https:\/\/www.linkedin.com\/in\/vincent-marion-27b25b208\/\">Vincent Marion<\/a><\/strong> (Inserm Universit\u00e9 de Strasbourg) &#8211; aujourd&#8217;hui Pr\u00e9sident d&#8217;AdipoPharma &#8211; cette recherche a fait \u00e9merger une piste th\u00e9rapeutique originale, ensuite <strong>port\u00e9e vers le d\u00e9veloppement industriel par CONECTUS (soci\u00e9t\u00e9 d&#8217;acc\u00e9l\u00e9ration du transfert de technologies), qui a investi financi\u00e8rement sur le projet<\/strong> \u00e0 une \u00e9tape tr\u00e8s amont de son d\u00e9veloppement (maturation, preuve de concept). <strong>Un engagement fondamental qui s&#8217;est concr\u00e9tis\u00e9 par la cr\u00e9ation de la startup AdipoPharma en 2017.<\/strong><\/p>\n<p><span style=\"font-size: 14pt; color: #c90f4c;\"><strong>Une innovation prometteuse face \u00e0 un enjeu mondial de sant\u00e9 publique<\/strong><\/span><\/p>\n<p>V\u00e9ritable probl\u00e8me de sant\u00e9 publique, le diab\u00e8te de type 2 touche des millions de personnes dans le monde. Il repr\u00e9sente un <strong>d\u00e9fi sanitaire majeur<\/strong>. En s\u2019attaquant \u00e0 la r\u00e9sistance \u00e0 l\u2019insuline plut\u00f4t qu\u2019en se limitant \u00e0 ses cons\u00e9quences, PATAS explore une voie th\u00e9rapeutique diff\u00e9rente, susceptible \u00e0 terme d\u2019\u00e9largir les options de traitement si son efficacit\u00e9 et sa s\u00e9curit\u00e9 sont confirm\u00e9es.<\/p>\n<p><strong>L\u2019entr\u00e9e en phase clinique 1b constitue donc une \u00e9tape strat\u00e9gique<\/strong>. Pour AdipoPharma, cette progression marque une nouvelle \u00e9tape dans le d\u00e9veloppement de son candidat m\u00e9dicament. Pour Conectus, elle t\u00e9moigne de l\u2019impact concret du transfert de technologie : transformer une d\u00e9couverte issue des laboratoires publics en une innovation susceptible, demain, de b\u00e9n\u00e9ficier aux patients. Du laboratoire aux essais cliniques, PATAS incarne ainsi une ambition forte : conduire la recherche alsacienne jusqu\u2019aux portes de l\u2019innovation th\u00e9rapeutique.<\/p>\n<p><span style=\"color: #c90f4c;\"><strong>&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8211;<br \/><a href=\"https:\/\/bit.ly\/4yKfn2P\" target=\"_blank\" rel=\"noopener\">Lire le communiqu\u00e9 de presse int\u00e9gral d&#8217;Adipopharma<\/a><br \/>&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8211;<\/strong><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AdipoPharma, cr\u00e9\u00e9e en 2017, poursuit un d\u00e9veloppement prometteur. Sa mol\u00e9cule PATAS entre en phase d\u2019\u00e9tude clinique 1b chez des patients atteints de diab\u00e8te de type 2. Une avanc\u00e9e majeure pour cette biotech strasbourgeoise, qui illustre concr\u00e8tement l&#8217;apport du transfert de technologie port\u00e9 par Conectus : transformer des d\u00e9couvertes scientifiques en innovations-sant\u00e9 au b\u00e9n\u00e9fice de toute [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":48840,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[535,536,603],"tags":[],"class_list":["post-48835","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-reussites","category-actualite","category-startup"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nouvelle avanc\u00e9e pour la startup AdipoPharma, propuls\u00e9e par Conectus - R\u00e9seau SATT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.satt.fr\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"France MANDRY\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.satt.fr\\\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\\\/\"},\"author\":{\"name\":\"France MANDRY\",\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/#\\\/schema\\\/person\\\/3c07a164c17f01f656480221ba81ab4e\"},\"headline\":\"Nouvelle avanc\u00e9e pour la startup AdipoPharma, propuls\u00e9e par Conectus\",\"datePublished\":\"2026-10-29T15:24:18+00:00\",\"dateModified\":\"2026-10-29T16:40:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\\\/\"},\"wordCount\":510,\"image\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.satt.fr\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Adipopharma-2.png\",\"articleSection\":[\"R\u00e9ussites\",\"Actualit\u00e9\",\"Startup\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.satt.fr\\\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\\\/\",\"url\":\"https:\\\/\\\/www.satt.fr\\\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\\\/\",\"name\":\"Nouvelle avanc\u00e9e pour la startup AdipoPharma, propuls\u00e9e par Conectus - R\u00e9seau SATT\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.satt.fr\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Adipopharma-2.png\",\"datePublished\":\"2026-10-29T15:24:18+00:00\",\"dateModified\":\"2026-10-29T16:40:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/#\\\/schema\\\/person\\\/3c07a164c17f01f656480221ba81ab4e\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.satt.fr\\\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.satt.fr\\\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.satt.fr\\\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.satt.fr\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Adipopharma-2.png\",\"contentUrl\":\"https:\\\/\\\/www.satt.fr\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Adipopharma-2.png\",\"width\":1920,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.satt.fr\\\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nouvelle avanc\u00e9e pour la startup AdipoPharma, propuls\u00e9e par Conectus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/\",\"name\":\"R\u00e9seau SATT\",\"description\":\"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/#\\\/schema\\\/person\\\/3c07a164c17f01f656480221ba81ab4e\",\"name\":\"France MANDRY\",\"url\":\"https:\\\/\\\/www.satt.fr\\\/en\\\/author\\\/france\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nouvelle avanc\u00e9e pour la startup AdipoPharma, propuls\u00e9e par Conectus - R\u00e9seau SATT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.satt.fr\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\/","twitter_misc":{"Written by":"France MANDRY","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.satt.fr\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\/#article","isPartOf":{"@id":"https:\/\/www.satt.fr\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\/"},"author":{"name":"France MANDRY","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/3c07a164c17f01f656480221ba81ab4e"},"headline":"Nouvelle avanc\u00e9e pour la startup AdipoPharma, propuls\u00e9e par Conectus","datePublished":"2026-10-29T15:24:18+00:00","dateModified":"2026-10-29T16:40:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.satt.fr\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\/"},"wordCount":510,"image":{"@id":"https:\/\/www.satt.fr\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2026\/10\/Adipopharma-2.png","articleSection":["R\u00e9ussites","Actualit\u00e9","Startup"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.satt.fr\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\/","url":"https:\/\/www.satt.fr\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\/","name":"Nouvelle avanc\u00e9e pour la startup AdipoPharma, propuls\u00e9e par Conectus - R\u00e9seau SATT","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.satt.fr\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\/#primaryimage"},"image":{"@id":"https:\/\/www.satt.fr\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2026\/10\/Adipopharma-2.png","datePublished":"2026-10-29T15:24:18+00:00","dateModified":"2026-10-29T16:40:04+00:00","author":{"@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/3c07a164c17f01f656480221ba81ab4e"},"breadcrumb":{"@id":"https:\/\/www.satt.fr\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.satt.fr\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.satt.fr\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\/#primaryimage","url":"https:\/\/www.satt.fr\/wp-content\/uploads\/2026\/10\/Adipopharma-2.png","contentUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2026\/10\/Adipopharma-2.png","width":1920,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/www.satt.fr\/nouvelle-avancee-pour-la-startup-adipopharma-propulsee-par-conectus\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.satt.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Nouvelle avanc\u00e9e pour la startup AdipoPharma, propuls\u00e9e par Conectus"}]},{"@type":"WebSite","@id":"https:\/\/www.satt.fr\/en\/#website","url":"https:\/\/www.satt.fr\/en\/","name":"R\u00e9seau SATT","description":"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.satt.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/3c07a164c17f01f656480221ba81ab4e","name":"France MANDRY","url":"https:\/\/www.satt.fr\/en\/author\/france\/"}]}},"_links":{"self":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/48835","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/comments?post=48835"}],"version-history":[{"count":3,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/48835\/revisions"}],"predecessor-version":[{"id":48842,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/48835\/revisions\/48842"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media\/48840"}],"wp:attachment":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media?parent=48835"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/categories?post=48835"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/tags?post=48835"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}